(325 days)
Not Found
No
The device description and performance studies focus on the physical components, material properties, and sterilization of a standard insulin syringe, with no mention of AI or ML.
Yes
The device is an insulin syringe, which is used for the subcutaneous injection of insulin, a medical treatment. Therefore, it is a therapeutic device.
No
Explanation: The device is an insulin syringe, intended for the subcutaneous injection of insulin, which is a therapeutic rather than a diagnostic function. The device description and performance studies focus on its ability to safely and effectively deliver a substance into the body, not to assess or identify a medical condition.
No
The device description clearly outlines physical components like a needle, barrel, and plunger, indicating it is a hardware medical device, not software-only.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is "subcutaneous injection of U-100 insulin." This describes a device used to administer a substance into the body, not to perform tests on samples taken from the body.
- Device Description: The description details the physical components of a syringe designed for injection (needle, barrel, plunger, etc.). There is no mention of components or functions related to analyzing biological samples.
- Lack of IVD-Specific Information: The document does not contain any information typically associated with IVD devices, such as:
- Analysis of biological samples (blood, urine, tissue, etc.)
- Detection or measurement of analytes
- Diagnostic purposes (identifying a disease or condition)
- Reagents or test kits
This device is clearly intended for the delivery of medication, which falls under the category of a therapeutic or drug delivery device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
Insulin syringes are intended for subcutaneous injection of U-100 insulin
Product codes (comma separated list FDA assigned to the subject device)
FMF
Device Description
The insulin syringe consists of needle cap, barrel, plunger stopper, needle tube and plunger cap. It is sterile disposable, non-pyrogenic, easy to use and meets all of the required standards. The plunger cap is optional. The single insulin syringe in unit package lacks the plunger cap compared with the product in the multi-unit package.
The needle cap is used to protect physical protection of the needle prior to use. The needle tube penetrates the patient's skin to inject fluid into the body. The plunger stopper is the sealing assembly that encloses mandrel component and is used to inject fluid into the body. The barrel is a tube-like and cylindrical structure that holds insulin before the injection. The plunger is the rod pushed down or up depending on clinical use. The plunger cap is used to protect plunger before use.
The capacity of the insulin device is 0.3 mL, 0.5 mL and 1 mL. The specification of needle tube is 26G, 27G, 28G, 29G, 30G, 31G, 32G and 33G. The needle length is 5 mm, 6 mm, 8 mm and 10 mm.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Adult and transitional adolescent
Intended User / Care Setting
Prescription Use (Part 21 CFR 801 Subpart D)
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The proposed device was tested and demonstrated to be in conformance with the following FDA recognized standards. The performance testing results met the standards' requirements to demonstrate the device's safety and effectiveness.
ISO 8537-2016: Sterile single-use syringes, with or without needle, for insulin
ISO 7886:1-2017: Sterile hypodermic syringes for single use – Part 1: Syringes for manual use
ISO 9626-2016: Stainless steel needle tubing for the manufacture of medical devices – Requirements and test methods
ISO 7864-2016: Sterile hypodermic needles for single use - Requirements and test methods
The proposed device was tested in compliance with ISO 10993-1, as the Externally Communicating Device, Blood Path Indirect, prolonged Contact (>24hrs to 30 days). Tests performed: Cytotoxicity, Sensitization, Irritation, Acute Systemic Toxicity, Hemocompatibility, Pyrogen, Subacute/Subchronic Toxicity, Genotoxicity.
Particulate testing was conducted in accordance with USP and USP. The testing results and met the USP acceptance criteria.
The sterilization process of the proposed device has been validated in compliance with ISO 11135. The EO and ECH residual doesn't exceed the limit according to ISO 10993-7.
The Shelf-Life validation study was conducted under accelerated aging conditions in compliance with ASTM F1980-16 to verify the claimed shelf-life of 5 years.
Package integrity testing under simulated shipping conditions was conducted to satisfy the requirements in ASTM D4169-16 Standard Practice for Performance Testing of Shipping Containers and Systems. All packaging was deemed acceptable for protection of product and sterility maintenance.
Sterile barrier testing was conducted in compliance with the following FDA-recognized consensus standards: Vacuum Leak Test, ASTM D3078-02; Dye Penetration Test ASTM F 1929-15; Microbial Barrier Properties Test DIN 58953-6: 2016; Seal Strength Test ASTM F88/F88M-21.
Simulated clinical use testing of the proposed device has been conducted in compliance with the FDA Guidance for industry and FDA Stuff, Medical Devices with Sharps Injury Prevention Features, August 9, 2005.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 880.5860 Piston syringe.
(a)
Identification. A piston syringe is a device intended for medical purposes that consists of a calibrated hollow barrel and a movable plunger. At one end of the barrel there is a male connector (nozzle) for fitting the female connector (hub) of a hypodermic single lumen needle. The device is used to inject fluids into, or withdraw fluids from, the body.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food & Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
November 30, 2023
Anhui Hongyu Wuzhou Medical Manufacturer Co., Ltd. % Evan Hu Technical and Regulatory Director Shanghai Mind-link Consulting Co., Ltd. 1399 Jiangyue Road, Minhang Shanghai, Shanghai 201114 China
Re: K230061
Trade/Device Name: Insulin Syringe Regulation Number: 21 CFR 880.5860 Regulation Name: Piston Syringe Regulatory Class: Class II Product Code: FMF Dated: June 19, 2023 Received: November 28, 2023
Dear Evan Hu:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
1
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely. Juliane C. Lessard -S
Juliane C. Lessard, Ph.D. Director DHT3C: Division of Drug Delivery and General Hospital Devices, and Human Factors OHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K230061
Device Name Insulin Syringe
| Indications for Use (Describe) |
|---|
| Insulin syringes are intended for subcutaneous injection of U-100 insulin |
| Type of Use (Select one or both, as applicable) | |
|---|---|
X Prescription Use (Part 21 CFR 801 Subpart D)
| | Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
K230061 510(k) Summary
-
- Preparation date: 06/19/2023
-
- Submitter
Manufacturer: Anhui Hongyu Wuzhou Medical Manufacturer Co., Ltd Address: No.2 Guanyin Road, Taihu Economic Development Zone Contact person: Xiang Bingyi, 86-556 5129666, hwj1@hongyu-wuzhou.cn Submission correspondent: Evan Hu, 86-18616124827, Evan.ww.hu@outlook.com
-
- Device
Trading name: Insulin Syringe Common name: Insulin Syringe Regulation No.: 21 CFR 880.5860 Classification name: Piston Syringe Classification: Class II Product code: FMF
- Device
-
- Predicate device
Predicate device: K220061-Safety Insulin Syringe
- Predicate device
-
- Device description
The insulin syringe consists of needle cap, barrel, plunger stopper, needle tube and plunger cap. It is sterile disposable, non-pyrogenic, easy to use and meets all of the required standards. The plunger cap is optional. The single insulin syringe in unit package lacks the plunger cap compared with the product in the multi-unit package.
- Device description
The needle cap is used to protect physical protection of the needle prior to use. The needle tube penetrates the patient's skin to inject fluid into the body. The plunger stopper is the sealing assembly that encloses mandrel component and is used to inject fluid into the body. The barrel is a tube-like and cylindrical structure that holds insulin before the injection. The plunger is the rod pushed down or up depending on clinical use. The plunger cap is used to protect plunger before use.
The capacity of the insulin device is 0.3 mL, 0.5 mL and 1 mL. The specification of needle tube is 26G, 27G, 28G, 29G, 30G, 31G, 32G and 33G. The needle length is 5 mm, 6 mm, 8 mm and 10 mm.
4
Table 1 Device specification
| Syringe unit
scale | Capacity
(mL) | Needle
gauge | Needle length | | | | | Wall type | Bevel angle |
|-----------------------|------------------|-----------------|---------------|-------------|--------------|--------------|--------------|----------------------------------|-------------------------|
| | | | 5mm
3/16" | 6mm
1/4" | 8mm
5/16" | 10mm
3/8" | 13mm
1/2" | Regular
wall and
Thin wall | Long and
short bevel |
| | 0.3 | 33G | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 32G | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 31G | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 30G | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 29G | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 28G | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 27G | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 26G | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| U-100
(Orange) | 0.5 | 33G | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 32G | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 31G | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 30G | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 29G | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 28G | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 27G | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 26G | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | 1 | 33G | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 32G | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 31G | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 30G | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 29G | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 28G | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 27G | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | 26G | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
"v" means that it is applicable in this configuration.
5
6. Indications for use
Insulin syringes are intended for subcutaneous injection of U-100 insulin.
-
- Comparison of technological characters between proposed and predicate device
7.1 Comparison of technological characters Table 2 Comparison table
- Comparison of technological characters between proposed and predicate device
| Characters | Proposed device
(K230061, Insulin syringe) | Primary predicate device
(K220061, Safety Insulin Syringe) | Remark |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Product code | FMF | FMF, MEG | Different #1 |
| Regulation No. | 21CFR 880. 5860 | 21CFR 880. 5860 | Same |
| Indications for use | Insulin syringes are intended for subcutaneous injection of U-100 insulin. | The Safety Insulin Syringe is a sterile, single use and non-reusable syringe intended for injection of U-100 insulin into the body, while reducing the risk of sharps injuries and the potential for insulin syringe reuse. | Different #2 |
| Environment of use | Prescription use | Prescription use | Same |
| Specific drug use | U-100 Insulins | U-100 Insulins | Same |
| Single use | Yes | Yes | Same |
| Label/labeling | Conforming to 21 CFR part 801 | Conforming to 21 CFR part 801 | Same |
| Non-pyrogenic | Yes | Yes | Same |
| Gauge size | 26G, 27G, 28G, 29G, 30G, 31G, 32G, 33G | 26G to 34G | Different #3 |
| Needle length | 5 mm, 6 mm, 8 mm, 10 mm, 13 mm | 4 mm, 5 mm, 6 mm, 8 mm, 9 mm, 10 mm, 12 mm, 13 mm | Different #4 |
| Hub/Needle bond strength | Min force: 70~110N
Conforming to ISO 8537: 2016 | Conforming to ISO 8537: 2016 | Same |
| Needle wall type | RW, TW | RW, TW, ETW | Different #5 |
| Needle tip and
bevel | Sharp tip
Bevel: Long beveled, short
beveled | Sharp tip
Bevel: unknown | Different
#6 |
| Configuration
and materials | Needle cap: Polyethylene;
Needle tube: 304 Stainless
steel;
Barrel: Polypropylene;
Plunger stopper: Synthetic
rubber;
Plunger : Polypropylene;
Plunger cap: Polyethylene; | Needle cap: Polypropylene;
Needle tube: 304 Stainless
steel;
Barrel: Polypropylene;
Plunger stopper: Polyisoprene
rubber;
Plunger: Polypropylene;
End cap: Polypropylene
Safety protector:
Polypropylene;
Fixed hub: Polypropylene;
Lubricant:
Polydimethylsiloxane;
Adhesive: UV Curing Adhesiv | Different
#7 |
| Capacity | 0.3 mL, 0.5 mL, 1mL | 0.3 mL, 0.5 mL, 1mL | Same |
| Sterilization
method | Sterilized by EO gas
SAL 10-6 | Sterilized by EO gas
SAL 10-6 | Same |
| Safety
performance | Not applicable | The force to activate the safety
mechanism is less than 5 N. The
force that the safety
mechanism is destroyed is
greater than 20 N. | Different
#8 |
| Needle
performance | Conforming to the
requirements of ISO 9626, ISO
7864 | Conforming to the
requirements of ISO 9626, ISO
7864 | Same |
| Syringe
performance | Conforming to the
requirements of ISO 7886-1 | Conforming to the
requirements of ISO 7886-1 | Same |
| Biocompatibility | Conforming to the
requirements of ISO 10993
series standards | Conforming to the
requirements of ISO 10993
series standards | Same |
| Shelf life | 5 years | 5 years | Same |
| Intended
population | Adult and transitional
adolescent | Adult and Pediatric | Different
#9 |
6
7.2 Substantial equivalence analysis
#1
The proposed device, coded as FMF, features a permanently attached needle. The predicate device is classified as an insulin syringe with antistick function, denoted by the product code FMF and MEG. Therefore, the proposed device falls within the same category as the predicate device. Both the proposed and predicate devices are designed for subcutaneous injection of
7
U-100 insulins and are intended for use by healthcare professionals. In conclusion, the proposed and the predicate device are substantially equivalent.
#2
The proposed device and predicate device are designed for the subcutaneous injection of U-100 insulins. The key distinction between them lies in the needle safety mechanism. The predicate device features a manually retractable needle for sharp injury protection and reuse prohibition, while the proposed device lacks a safety protection feature. However, this absence does not impact the functionality of the product.
In conclusion, the proposed and the predicate device are substantially equivalent.
#3 & #4 & #5
The proposed device exhibits gauge size, needle length and needle wall type that differs from the predicate device, but it falls within the range of the predicate device. Comprehensive performance testing has confirmed that the proposed device meets all the requirements stipulated by relevant standards or quidance, indicating a substantial equivalence. Any disparities in gauge size, needle length and needle wall type between the predicate and subject devices were effectively addressed through the execution of ISO 7864:2016 and ISO 9626:2016 performance testing protocols.
In conclusion, the proposed device and the predicate device are substantially equivalent.
#6
Both the proposed and predicate devices utilize typical sharp needles. The specific needle bevel of the predicate device is not disclosed. Healthcare professionals typically select the appropriate device based on clinical circumstances. This dissimilarity does not impact the intended functionality and has been accounted for through performance testing conducted in accordance with ISO 7864:2016 and ISO 9626:2016.
In conclusion, the proposed device and the predicate device are substantially equivalent.
#7
The materials used for the needle cap and plunger cap in the proposed device are not identical to those in the predicate device. The primary components share the same materials. However, it is important to note that the needle cap and plunger cap do not come into direct contact with patients. Despite this, comprehensive biocompatibility and performance tests have been conducted to verify the safety and effectiveness of all materials used in the device. In conclusion, the proposed device and the predicate device are substantially equivalent.
#8
The proposed device is a conventional insulin syringe. whereas the predicate device is a safety insulin syringe. The non-safety syringe is commonly utilized in clinical settings. Performance tests have been conducted to validate the safety and efficacy of the proposed device. In conclusion, the proposed device and the predicate device are substantially equivalent.
#9
The proposed device has a different intended population aqe (>18 years old), but fall within the population age range (Adult and pediatric) of the predicate device. Performance tests have been conducted to validate the safety and efficacy of the proposed device. In conclusion, the proposed device and the predicate device are substantially equivalent.
8
8. Non-clinical testing
PERFORMANCE TESTING
The proposed device was tested and demonstrated to be in conformance with the following FDA recognized standards. The performance testing results met the standards' requirements to demonstrate the device's safety and effectiveness.
ISO 8537-2016: Sterile single-use syringes, with or without needle, for insulin
- " Limits for acidity or alkalinity
- . Limits for extractable metals
- . Tolerance on the graduated capacity
- . Graduation lines
- Numbering of scale "
- " Scale interval units
- Overall length of scale .
- . Barrel and plunger stopper
- Finger grips "
- Fit of plunger stopper in barrel .
- . Dead space
- Freedom from leakage past plunger stopper .
- Bond between hub and needle tube .
- Needle cap .
ISO 7886:1-2017: Sterile hypodermic syringes for single use – Part 1: Syringes for manual use
-
. Lubricant of syringe
ISO 9626-2016: Stainless steel needle tubing for the manufacture of medical devices – Requirements and test methods -
Stiffness .
-
. Resistance to Breakage
-
Resistance to Corrosion .
-
. Needle O.D.
-
. Needle inner diameter
ISO 7864-2016: Sterile hypodermic needles for single use - Requirements and test methods
- Needle point .
9
- Patency of lumen "
- . Cleanliness
- Needle length .
- . Lubricant of needle tube
- Penetration force and drag force for needles .
BIOCOMPATIBILITY TESTING
The proposed device was tested in compliance with ISO 10993-1, as the Externally Communicating Device, Blood Path Indirect, prolonged Contact (>24hrs to 30 days).
- . Cytotoxicity
- . Sensitization
- " Irritation
- Acute Systemic Toxicity .
- Hemocompatibility "
- . Pyrogen
- Subacute/Subchronic Toxicity .
- . Genotoxicity
Particulate testing was conducted in accordance with USP and USP. The testing results and met the USP acceptance criteria.
STERILE, PACKAGE AND SHELF-LIFE VALIDATION
The sterilization process of the proposed device has been validated in compliance with ISO 11135. The EO and ECH residual doesn't exceed the limit according to ISO 10993-7.
The Shelf-Life validation study was conducted under accelerated aging conditions in compliance with ASTM F1980-16 to verify the claimed shelf-life of 5 years.
Package integrity testing under simulated shipping conditions was conducted to satisfy the requirements in ASTM D4169-16 Standard Practice for Performance Testing of Shipping Containers and Systems. All packaging was deemed acceptable for protection of product and sterility maintenance.
Sterile barrier testing was conducted in compliance with the following FDA-recognized consensus standards.
- . Vacuum Leak Test, ASTM D3078-02;
- . Dye Penetration Test ASTM F 1929-15;
10
- Microbial Barrier Properties Test DIN 58953-6: 2016; "
- . Seal Strength Test ASTM F88/F88M-21.
SIMULATED CLINICAL USE TESTING
Simulated clinical use testing of the proposed device has been conducted in compliance with the FDA Guidance for industry and FDA Stuff, Medical Devices with Sharps Injury Prevention Features, August 9, 2005.
-
- Clinical testing
Not applicable for this submission.
- Clinical testing
10. Conclusion
The differences between the proposed and the predicate device do not raise any new or different questions of safety or effectiveness. The proposed device is substantially equivalent to the predicate device with respect to indications for use and technological characteristics.